Atrial Fibrillation Study with Abelacimab Stopped Early by the Data Monitoring Committee Due to an Overwhelming Reduction in Bleeding as Compared to a DOAC

Abelacimab, a Dual-Acting Factor XI / XIa Inhibitor, Demonstrated an Unprecedented Reduction in Bleeding in the Largest and Longest Head-toHead Study Comparing a Factor XI Inhibitor to a DOAC 

Related Keywords

United States ,American ,Lewis Dexter ,Thromb Haemost ,Marcs Sabatine ,Dan Bloomfield ,Coll Cardiol ,Harvard Medical School ,Data Monitoring Committee ,Blackstone Life Sciences ,Study Group ,National Blood Clot Alliance ,Anthos Therapeutics Inc ,Anthos Therapeutics ,Distinguished Chair ,Cardiovascular Medicine ,Myocardial Infarction ,New England Journal ,Chief Medical Officer ,Disease Control ,Leslie Lake ,National Blood Clot ,Englj Med July ,Atrial Fibrillation ,American Heart Journal ,